The American Society of Clinical Oncology (ASCO) has reviewed complications associated with immune checkpoint inhibitor therapy.
Patient selection: thyrotoxicosis following therapy with an immune checkpoint inhibitor
Laboratory features: low serum TSH, elevated FT4 and/or FT3
Parameters:
(1) clinical signs and symptoms
(2) ability to perform activities of daily living (ADL)
|
Clinical Signs and Symptoms
|
Activities of Daily Living
|
Grade
|
|
none or mild
|
able to perform
|
G1
|
|
moderate
|
able to perform
|
G2
|
|
severe
|
unable to perform
|
G3
|
|
life-threatening
|
unable to perform
|
G4
|
The diagnosis requires exclusion of pre-existing thyrotoxicosis.
